Huntington Beach Mobile App Cross Platform Development
BASIC
- Around 5 Screens.
- Around 5 Integrations
- Only simple validations on device
- No-obligation inquiry.
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
STANDARD
- Around 10 Screens
- Around 10 Integrations
- Simple business logic for Validations / Calculations / Chart Data etc.
- Some local storage of data
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
- 1 Project Manager (shared)
- 1 Team Lead (shared)
PREMIUM
- Around 20 Screens
- Around 20 Integrations
- Complex business logic like Interactive Charts, Animations, Validations, Conditions etc.
- Complete local storage of data used by App
- We will create suggestions on monthly basis for improvement for you.
Cross-Platform App Development Services & Solutions in Huntington Beach
We take your groundwork and create a market-ready app based on your needs while you focus on product and company growth.
Flutter is the fastest-growing cross-platform development framework. It was introduced in 2017 by Google and managed to gain great popularity among cross-platform programmers.
Huntington Beach News
Supreme Court rejects Huntington Beach appeal over state housing laws
The U.S. Supreme Court has refused to hear Huntington Beach's appeal, forcing the city to comply with California's state-mandated affordable housing laws.
Black History Centennial Celebration at Marshall University
Although February has come to end, there are more events in store. Burnis Morris, Director of the Dr. Carter G. Woodson Lyceum at Marshall University, stopped by First Look at Four to explain.
UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy
Shares of uniQure plummeted more than 40% in premarket trading Monday after the company confirmed the FDA has rejected its current data package for AMT-130, a highly anticipated gene therapy for ...
New FDA knockback hits uniQure and Huntington patients hard
uniQure held a Type A meeting with the FDA at the end of January and, in a statement released today, said the agency "cannot agree that data from the Phase I/II studies, compared to an external ...